Hepatobiliary, Pancreatic & Splenic Surgery

Strasberg A (cystic duct stump or duct of Luschka leak): ERCP with biliary sphincterotomy and transpapillary stenting (>90–95% closure) plus percutaneous biloma drainage. Strasberg E1–E5 major transection: if recognized intraoperatively with an HPB surgeon immediately available, perform a tension-free Roux-en-Y hepaticojejunostomy; if recognized postoperatively, drain the biloma, control sepsis, map the vascular and biliary anatomy (CT angiography + MRCP), and refer to a specialized HPB center for delayed Roux-en-Y hepaticojejunostomy at 6–8 weeks.

Before: Immediate primary end-to-end ductal repair over a T-tube by the non-HPB index surgeon, or delayed unguided exploratory laparotomy during active biliary peritonitis.

Now: Strasberg A (cystic duct stump or duct of Luschka leak): ERCP with biliary sphincterotomy and transpapillary stenting (>90–95% closure) plus percutaneous biloma drainage. Strasberg E1–E5 major transection: if recognized intraoperatively with an HPB surgeon immediately available, perform a tension-free Roux-en-Y hepaticojejunostomy; if recognized postoperatively, drain the biloma, control sepsis, map the vascular and biliary anatomy (CT angiography + MRCP), and refer to a specialized HPB center for delayed Roux-en-Y hepaticojejunostomy at 6–8 weeks.

Patients with post-cholecystectomy bile leak (Strasberg Type A) and patients with major transectional bile duct injury (Strasberg E1–E5), exactly as the addendum's summary row stratifies them.

Attempted repair by the non-HPB primary surgeon during active inflammation carries >60–75% stricture failure, whereas specialist HPB Roux-en-Y hepaticojejunostomy achieves >90% long-term patency — the referral and timing discipline is the practice change, not an optional preference.

• WSES Bile Duct Injury Guidelines — as cited in the addendum summary table (no PMID printed)
• Multi-Society BDI Consensus 2020 (Brunt et al.) — as cited in the addendum summary table (no PMID printed)

Perform complete extrahepatic bile duct cyst excision down to the intrapancreatic pancreaticobiliary junction, combined with cholecystectomy and bilioenteric reconstruction via Roux-en-Y hepaticojejunostomy.

Before: Internal cyst-enterostomy drainage (cystoduodenostomy or cystojejunostomy) leaving the diseased cyst wall in situ.

Now: Perform complete extrahepatic bile duct cyst excision down to the intrapancreatic pancreaticobiliary junction, combined with cholecystectomy and bilioenteric reconstruction via Roux-en-Y hepaticojejunostomy.

Adults with congenital choledochal cysts — Todani Type I (fusiform/saccular) and Type IVa (extrahepatic/intrahepatic) cysts, exactly as the addendum's summary row states them.

Anomalous pancreaticobiliary ductal union exposes the biliary epithelium to refluxed activated pancreatic enzymes, carrying a 10–30% lifetime risk of cholangiocarcinoma that internal drainage fails to eliminate — leaving the cyst wall in situ is the harm this change removes.

• Japanese Study Group on Pancreaticobiliary Maljunction (JSPBM) / International HPB Consensus — as cited in the addendum summary table (no PMID printed)

Do not promote UDCA as a universal mandate after all bariatric operations; keep the overall neutral primary result (p = 0.071) visible. Consider selective 6-month UDCA prophylaxis (900 mg/day) in patients without baseline gallstones undergoing Roux-en-Y gastric bypass — the prespecified subgroup in which UPGRADE showed benefit.

Before: Prophylactic ursodeoxycholic acid (UDCA) promoted routinely after bariatric operations to prevent symptomatic gallstone disease (converse of the book's printed practice implication — the §3.0 bullet and Trial 3.4 appraisal print no outdated-routine cell).

Now: Do not promote UDCA as a universal mandate after all bariatric operations; keep the overall neutral primary result (p = 0.071) visible. Consider selective 6-month UDCA prophylaxis (900 mg/day) in patients without baseline gallstones undergoing Roux-en-Y gastric bypass — the prespecified subgroup in which UPGRADE showed benefit.

Adults with an intact gallbladder scheduled for laparoscopic Roux-en-Y gastric bypass (92% of the trial) or sleeve gastrectomy (8%). UPGRADE randomized 985 patients; 959 had primary-endpoint data (475 UDCA vs. 484 placebo); 20% (189) had asymptomatic gallstones on baseline ultrasound.

Overall primary endpoint was NOT statistically significant: symptomatic gallstone disease within 24 months occurred in 6.5% (31/475) on UDCA vs. 9.7% (47/484) on placebo (relative risk 0.67, 95% CI 0.43–1.04; p = 0.071). The prespecified subgroup interaction with baseline asymptomatic gallstones was significant (p_interaction = 0.046): UDCA reduced symptomatic gallstones in patients without baseline gallstones (RR 0.47, 95% CI 0.27–0.84; p = 0.0081) — particularly stone-free RYGB (RR 0.37, 95% CI 0.20–0.71; p = 0.0016) — but had no effect in patients with baseline asymptomatic stones (RR 1.22, 95% CI 0.61–2.47; p = 0.57). The sleeve gastrectomy subgroup (n = 78, 8%) was too small for definitive conclusions, and medication adherence was moderate (63% took >=80% of doses).

• UPGRADE Trial — Haal S et al., Lancet Gastroenterol Hepatol 2021 (PMID 34715031; Ref. 22)

Early laparoscopic cholecystectomy (generally favored within 72 hours of admission or up to 7 days of symptom onset under TG18/WSES guidance), individualized to clinical severity (Grade I–III), physiological fitness for general anesthesia, local tissue planes, and laparoscopic HPB expertise.

Before: Routine conservative antibiotic cooling followed by delayed interval cholecystectomy 6–8 weeks later for all admissions, or treating 72 hours / 7 days as an absolute cutoff that automatically prohibits early surgery.

Now: Early laparoscopic cholecystectomy (generally favored within 72 hours of admission or up to 7 days of symptom onset under TG18/WSES guidance), individualized to clinical severity (Grade I–III), physiological fitness for general anesthesia, local tissue planes, and laparoscopic HPB expertise.

Adults with acute calculous cholecystitis (TG18 graded). Outcomes rated in the matrix: recurrent biliary events, major complications, and hospital stay.

Early cholecystectomy prevents waiting-period biliary readmissions (18%–25%) and shortens hospital stay. Crossing 72 hours or 7 days does not automatically make early surgery inappropriate if clinical status and surgical expertise allow; conversely, physiologically unfit patients require resuscitation and gallbladder drainage. Do not conflate 'high risk' (such as APACHE II 7–14 in the CHOCOLATE trial, where patients able to tolerate general anesthesia benefited from early laparoscopic cholecystectomy — major complications 12% [8/66] vs. 65% [44/68] with percutaneous drainage; RR 0.19, 95% CI 0.10–0.37; P < 0.001) with 'physiologically unfit for surgery' (refractory septic shock, severe cardiopulmonary decompensation, or APACHE II >= 15, where urgent percutaneous or endoscopic gallbladder drainage is indicated) (§3.0 Guardrail 1; CHOCOLATE figures as printed in §3.0).

Regional clinical practice consideration (§3.0 Saudi/GCC frame): perioperative hematology coordination for pigment gallstones in patients with sickle cell disease or beta-thalassemia in high-prevalence Saudi provinces — presented as a regional practice consideration rather than a nationally mandated screening protocol.

• Tokyo Guidelines TG18 — Okamoto et al. (PMID 29045062)
• CHOCOLATE RCT — Loozen et al., BMJ 2018 (PMID 30297544)
• WSES Guidelines — as cited in Table 3.1

Moderate goal-directed Lactated Ringer's resuscitation: 10 mL/kg bolus ONLY if hypovolemic (none if normovolemic), followed by 1.5 mL/kg/h infusion with clinical/hematocrit/BUN reassessment at 12, 24, 48, and 72 hours. Initiate early oral feeding within 24–48 hours as pain improves (or nasogastric/nasojejunal enteral nutrition if oral intake fails at 72 h); omit prophylactic antibiotics in sterile necrosis.

Before: Aggressive fluid resuscitation (20 mL/kg bolus followed by 3 mL/kg/h infusion), prolonged NPO bowel rest, and prophylactic carbapenem antibiotics for sterile necrosis.

Now: Moderate goal-directed Lactated Ringer's resuscitation: 10 mL/kg bolus ONLY if hypovolemic (none if normovolemic), followed by 1.5 mL/kg/h infusion with clinical/hematocrit/BUN reassessment at 12, 24, 48, and 72 hours. Initiate early oral feeding within 24–48 hours as pain improves (or nasogastric/nasojejunal enteral nutrition if oral intake fails at 72 h); omit prophylactic antibiotics in sterile necrosis.

Initial intravenous fluid resuscitation and nutritional support in acute pancreatitis.

WATERFALL (n = 249) was halted early after aggressive fluids tripled fluid overload (20.5% vs. 6.3%; adjusted RR 2.85, p = 0.004) without reducing moderately severe/severe pancreatitis (22.1% vs. 17.3%).

• WATERFALL Trial — de-Madaria E et al., N Engl J Med 2022 (PMID 36103415; Ref. 90)
• IAP/APA & ACG Guidelines — as cited in Addendum §10.1

Administer polyvalent pneumococcal (PCV20 or PCV15→PPSV23), quadrivalent meningococcal (MenACWY) + MenB, and Haemophilus influenzae type b (Hib) vaccines ≥14 days BEFORE elective splenectomy (or ≥14 days postoperatively after emergency splenectomy). Perform laparoscopic splenectomy (hand-assisted if massive >20 cm), systematically inspect the splenic hilum, gastrocolic/splenocolic ligaments, tail of pancreas, and greater omentum for accessory spleens (present in 10–15% of ITP cases), and administer extended LMWH prophylaxis with Doppler surveillance in splenomegaly/myeloproliferative patients.

Before: Open splenectomy without preoperative vaccination, omitting intraoperative search for accessory spleens in ITP, or omitting postoperative portal vein thrombosis prophylaxis in massive splenomegaly.

Now: Administer polyvalent pneumococcal (PCV20 or PCV15→PPSV23), quadrivalent meningococcal (MenACWY) + MenB, and Haemophilus influenzae type b (Hib) vaccines ≥14 days BEFORE elective splenectomy (or ≥14 days postoperatively after emergency splenectomy). Perform laparoscopic splenectomy (hand-assisted if massive >20 cm), systematically inspect the splenic hilum, gastrocolic/splenocolic ligaments, tail of pancreas, and greater omentum for accessory spleens (present in 10–15% of ITP cases), and administer extended LMWH prophylaxis with Doppler surveillance in splenomegaly/myeloproliferative patients.

Elective splenectomy for hematologic disorders (refractory ITP, hereditary spherocytosis, thalassemia/sickle cell hypersplenism) and OPSI / portal vein thrombosis prevention.

Overwhelming Post-Splenectomy Infection (OPSI) carries >50% mortality (Streptococcus pneumoniae, Neisseria meningitidis, H. influenzae); missed accessory spleens cause refractory ITP relapse, and portal/splenic vein thrombosis occurs in 5–15% of splenomegaly resections.

Saudi & Gulf frame (§10.0): regional endemic hemoglobinopathy splenectomy pathways (thalassemia/sickle cell hypersplenism) integrate pre-splenectomy vaccination ≥14 days prior to elective laparoscopic splenectomy and post-splenectomy portal/splenic vein thrombosis surveillance.

• EAES Laparoscopic Splenectomy Guidelines — as cited in Addendum §10.1
• CDC ACIP Asplenia Immunization Schedule — as cited in Addendum §10.1

Apply the 2022 ESGAR/EAES/EFISDS/ESGE joint guideline for true polyps: cholecystectomy if >=10 mm (or 6–9 mm with >=1 risk factor: age >60 years, PSC, Asian ethnicity, or sessile polyp/focal wall thickening >4 mm) in surgically fit patients; US surveillance at 6, 12, and 24 months (stop at 2 years if no growth) for 6–9 mm without risk factors or <=5 mm with risk factors; no follow-up for <=5 mm without risk factors. Separate pathway: urgent cross-sectional staging and HPB oncology referral for any suspected gallbladder cancer (infiltrating mass, irregular mural thickening, invasion).

Before: Routine cholecystectomy for all polyps >= 6 mm without risk stratification, mixing 2017 and 2022 guideline criteria, or placing suspicious infiltrating wall thickening/masses into polyp ultrasound surveillance.

Now: Apply the 2022 ESGAR/EAES/EFISDS/ESGE joint guideline for true polyps: cholecystectomy if >=10 mm (or 6–9 mm with >=1 risk factor: age >60 years, PSC, Asian ethnicity, or sessile polyp/focal wall thickening >4 mm) in surgically fit patients; US surveillance at 6, 12, and 24 months (stop at 2 years if no growth) for 6–9 mm without risk factors or <=5 mm with risk factors; no follow-up for <=5 mm without risk factors. Separate pathway: urgent cross-sectional staging and HPB oncology referral for any suspected gallbladder cancer (infiltrating mass, irregular mural thickening, invasion).

Adults with gallbladder polypoid lesions on transabdominal ultrasound vs. suspicious mural/mass lesions. Outcomes rated in the matrix: early malignancy detection and avoidance of unnecessary cholecystectomy.

In ESGAR 2022, growth to >=10 mm warrants cholecystectomy, whereas growth of >=2 mm within 2 years in a polyp still <10 mm prompts reassessment of current size, patient risk factors, and multidisciplinary discussion. Asian ethnicity (extended in 2022 from Indian ethnicity in 2017) is interpreted alongside size, morphology, symptoms, and surgical fitness rather than as a standalone surgical mandate. Never place an infiltrating gallbladder mass, porcelain/irregular wall thickening, or suspected malignancy into a routine polyp ultrasound surveillance schedule or perform casual simple cholecystectomy without cross-sectional staging and specialist HPB oncology referral (§3.0 Guardrail 4).

• 2022 ESGAR / EAES / EFISDS / ESGE Joint Guideline — Foley et al., Eur Radiol 2022 (PMID 34918177)

Stage-matched WHO-IWGE management, stratified by cyst size exactly as the WHO-IWGE Expert Consensus stage-specific table prints it: (1) Active unilocular CE1 and transitional CE3a cysts: <5 cm — albendazole alone (10–15 mg/kg/day); >5 cm — PAIR (Puncture, Aspiration, Injection of scolicidal 20% hypertonic saline/ethanol after excluding biliary communication, Re-aspiration) + albendazole. (2) Multivesicular CE2/CE3b cysts, at any size: non-PAIR percutaneous treatment + albendazole, or surgery; complicated cysts (including cystobiliary fistula) go to surgery — perioperative albendazole + conservative unroofing/partial cystectomy with direct suturing of biliary orifices and omentoplasty (or pericystectomy), using 20%-hypertonic-saline-soaked packs around the field. (3) Inactive calcified CE4–CE5, at any size: 'watch-and-wait' observation without surgery.

Before: Uniform open surgical exploration for all hepatic hydatid cysts regardless of WHO-IWGE viability stage, or injecting scolicidal solution before checking for bile communication.

Now: Stage-matched WHO-IWGE management, stratified by cyst size exactly as the WHO-IWGE Expert Consensus stage-specific table prints it: (1) Active unilocular CE1 and transitional CE3a cysts: <5 cm — albendazole alone (10–15 mg/kg/day); >5 cm — PAIR (Puncture, Aspiration, Injection of scolicidal 20% hypertonic saline/ethanol after excluding biliary communication, Re-aspiration) + albendazole. (2) Multivesicular CE2/CE3b cysts, at any size: non-PAIR percutaneous treatment + albendazole, or surgery; complicated cysts (including cystobiliary fistula) go to surgery — perioperative albendazole + conservative unroofing/partial cystectomy with direct suturing of biliary orifices and omentoplasty (or pericystectomy), using 20%-hypertonic-saline-soaked packs around the field. (3) Inactive calcified CE4–CE5, at any size: 'watch-and-wait' observation without surgery.

Hepatic cystic echinococcosis (Hydatid cyst of the liver, Echinococcus granulosus) across WHO-IWGE ultrasound stages CE1–CE5.

PAIR fails and recurs in multivesicular CE2/CE3b daughter cysts, while operating on dead calcified CE4–CE5 cysts causes unnecessary biliary morbidity; excluding biliary fistula before scolicidal instillation prevents sclerosing cholangitis. Never inject scolicidal agents (20% hypertonic saline, cetrimide, or 95% ethanol) into a hepatic hydatid cyst if bile staining or cystobiliary communication is present — caustic sclerosing cholangitis is a devastating, irreversible complication (§10.0 red flag).

Saudi & Gulf frame (§10.0/§10.2): hepatic hydatid disease remains endemic in pastoral regions of the Kingdom — regional pathways integrate WHO-IWGE CE1–CE5 staging, perioperative oral albendazole (10–15 mg/kg/day in 2 divided doses, starting ≥1–4 weeks preoperatively and continuing 1–3 months postoperatively, monitoring LFTs and CBC), shielding of the peritoneal cavity with hypertonic (20%) saline-soaked packs, and careful testing of cyst fluid for bilirubin/bile staining before any scolicidal instillation.

• WHO-IWGE Expert Consensus on Cystic Echinococcosis — as cited in Addendum §10.1

Operational bailout pathway: (1) stop hilar dissection; (2) call for senior/HPB assistance; (3) document anatomy and consider intraoperative imaging (IOC, laparoscopic US, or NIRF-ICG); and (4) select an appropriate bailout — subtotal cholecystectomy (fenestrating or reconstituting), fundus-first dissection in suitable anatomy, conversion to open surgery when it aids exposure/palpation, or cholecystostomy drainage.

Before: Continued hazardous hilar dissection in an obliterated Calot triangle, dividing tubular structures before all three CVS elements are confirmed, or assuming conversion to open surgery alone guarantees safe duct identification.

Now: Operational bailout pathway: (1) stop hilar dissection; (2) call for senior/HPB assistance; (3) document anatomy and consider intraoperative imaging (IOC, laparoscopic US, or NIRF-ICG); and (4) select an appropriate bailout — subtotal cholecystectomy (fenestrating or reconstituting), fundus-first dissection in suitable anatomy, conversion to open surgery when it aids exposure/palpation, or cholecystostomy drainage.

Patients with a hostile hepatocystic triangle during cholecystectomy. Outcomes rated in the matrix: major bile duct injury prevention, postoperative bile leak, and remnant stone recurrence.

In heterogeneous observational series (e.g., Elshaer et al., n = 1,231; Henneman et al.), fenestrating subtotal cholecystectomy had higher transient bile leak (~15%–18%) and lower remnant stone recurrence (~1%–4%), whereas reconstituting subtotal had lower early bile leak (~4%–7%) and higher remnant gallstone recurrence (~5%–15%). These are study-level observational ranges with variable follow-up, not a rigid formula; technique depends on infundibular mobility, inflammation, and surgeon judgment. Improved duct visualization with near-infrared ICG cholangiography (FALCON) is a surrogate outcome, not proof of fewer major bile duct injuries; ICG never replaces the 3-element Strasberg Critical View of Safety or indicated intraoperative cholangiography (§3.0 Guardrail 3).

Verify ICG product-specific contraindications (prior ICG hypersensitivity vs. sodium iodide label warnings) under local Saudi SFDA/national labeling, and note that severe hepatic dysfunction impairs hepatic uptake and biliary excretion of ICG (§3.0 Guardrail 3).

• Multi-Society Safe Cholecystectomy Guideline 2020 — Brunt et al. (PMID 32404658)
• FALCON RCT — van den Bos et al., Surg Endosc 2023 (PMID 36849564)
• Elshaer et al. Systematic Review, JAMA Surg 2015 — as cited in Table 3.1

Antibiotic-first and delayed step-up approach: initiate targeted IV antibiotics (carbapenem or fluoroquinolone/metronidazole) and postpone endoscopic transluminal (LAMS/pigtail) or retroperitoneal percutaneous catheter drainage until walled-off necrosis (WON) is encapsulated (typically ≥4 weeks from onset) unless refractory septic shock/abdominal compartment syndrome forces earlier drainage; escalate to endoscopic necrosectomy or VARD only if drainage fails.

Before: Early open surgical necrosectomy or immediate catheter drainage within 24 hours of diagnosing infected acute necrotic collection.

Now: Antibiotic-first and delayed step-up approach: initiate targeted IV antibiotics (carbapenem or fluoroquinolone/metronidazole) and postpone endoscopic transluminal (LAMS/pigtail) or retroperitoneal percutaneous catheter drainage until walled-off necrosis (WON) is encapsulated (typically ≥4 weeks from onset) unless refractory septic shock/abdominal compartment syndrome forces earlier drainage; escalate to endoscopic necrosectomy or VARD only if drainage fails.

Timing and modality of intervention for infected necrotizing pancreatitis.

In POINTER (n = 104), postponed drainage required fewer total interventions (mean 2.6 vs. 4.4) with similar Comprehensive Complication Index (57 vs. 58), and 39% of patients in the postponed group survived with antibiotics alone without any drainage or necrosectomy.

• POINTER Trial — Boxhoorn L et al., N Engl J Med 2021 (PMID 34614330; Ref. 91)
• PANTER & TENSION Trials — as cited in Addendum §10.1

Hemangioma & FNH (confirmed on hepatobiliary-specific gadoxetate MRI): reassure, do NOT biopsy, and do NOT stop oral contraceptives (resect only giant symptomatic/compressive lesions). Hepatocellular Adenoma (HCA): resect all HCAs in MEN (regardless of size due to high beta-catenin malignancy risk); in women, stop estrogen/OCPs and weight-optimize — resect if persistently ≥5 cm after 6 months or if beta-catenin-mutated. Resectable HCC (BCLC 0/A, Child-Pugh A, no portal hypertension) & CRLM: parenchymal-sparing R0 resection preserving ≥20–25% Future Liver Remnant (FLR) in normal liver, ≥30% in post-chemo steatotic liver, and ≥40% in cirrhosis.

Before: Percutaneous biopsy or elective resection of asymptomatic hepatic hemangiomas and FNH, or routine resection of all hepatocellular adenomas regardless of sex and size.

Now: Hemangioma & FNH (confirmed on hepatobiliary-specific gadoxetate MRI): reassure, do NOT biopsy, and do NOT stop oral contraceptives (resect only giant symptomatic/compressive lesions). Hepatocellular Adenoma (HCA): resect all HCAs in MEN (regardless of size due to high beta-catenin malignancy risk); in women, stop estrogen/OCPs and weight-optimize — resect if persistently ≥5 cm after 6 months or if beta-catenin-mutated. Resectable HCC (BCLC 0/A, Child-Pugh A, no portal hypertension) & CRLM: parenchymal-sparing R0 resection preserving ≥20–25% Future Liver Remnant (FLR) in normal liver, ≥30% in post-chemo steatotic liver, and ≥40% in cirrhosis.

Benign solid liver lesions (Hemangioma, Focal Nodular Hyperplasia [FNH], vs. Hepatocellular Adenoma [HCA]) and resectable HCC / Colorectal Liver Metastases (CRLM).

Hemangiomas and FNH have zero malignant potential; in HCA, male sex, beta-catenin exon 3 mutation, and diameter ≥5 cm carry elevated hemorrhage (15–20%) and HCC transformation (5–10%) risk.

Saudi & Gulf frame (§10.0): regional HCC practice integrates the SASLT (Saudi Association for the Study of Liver Diseases and Transplantation) Hepatocellular Carcinoma & Portal Hypertension Guidelines alongside the international standard this card carries.

• EASL / AASLD 2023 Benign & Malignant Liver Tumor Guidelines — as cited in Addendum §10.1

Same-admission laparoscopic cholecystectomy in eligible patients recovering from mild, non-necrotizing gallstone pancreatitis once pain resolves, oral diet is tolerated, and CBD stones are addressed; defer surgery in moderate/severe pancreatitis with persistent organ failure, necrosis, or significant peripancreatic fluid collections.

Before: Routine discharge after biochemical recovery with interval cholecystectomy 4–6 weeks later in uncomplicated mild pancreatitis, or applying same-admission surgery unselectively to necrotizing/severe pancreatitis.

Now: Same-admission laparoscopic cholecystectomy in eligible patients recovering from mild, non-necrotizing gallstone pancreatitis once pain resolves, oral diet is tolerated, and CBD stones are addressed; defer surgery in moderate/severe pancreatitis with persistent organ failure, necrosis, or significant peripancreatic fluid collections.

Recovering adults with mild biliary pancreatitis (no organ failure or necrosis, CRP < 100 mg/L, oral intake restored, off opioids). Outcome rated in the matrix: 6-month gallstone-related readmission or death.

In PONCHO (n = 264 ITT), same-admission cholecystectomy (within 3 days of randomization) reduced the 6-month composite of death or gallstone-related readmission from 17% (23/136) to 5% (6/128; RR 0.28, 95% CI 0.12–0.66; p = 0.002), including recurrent pancreatitis (9% vs. 2%), without increasing surgical complications. Excludes necrotizing/severe pancreatitis, ASA IV, and ASA III aged >75 years. Do not apply same-admission cholecystectomy as a blanket rule to moderate or severe acute pancreatitis with persistent organ failure, pancreatic necrosis, or evolving peripancreatic collections (§3.0 Guardrail 2).

• PONCHO RCT — da Costa et al., Lancet 2015 (PMID 26460661)
• TG18 / IAP-APA Guidelines — as cited in Table 3.1 (TG18: Okamoto et al., PMID 29045062)

Serous cystadenoma (microcystic honeycomb/central scar, low CEA, high glucose): observe unless symptomatic. Main-duct IPMN (MPD ≥10 mm) or Branch-Duct IPMN with High-Risk Stigmata (obstructive jaundice, enhancing mural nodule ≥5 mm, MPD ≥10 mm, positive/high-grade cytology): oncologic pancreatectomy (Whipple or distal pancreatectomy) in fit patients. BD-IPMN with Worrisome Features (cyst ≥3 cm, MPD 5–9 mm, mural nodule <5 mm, growth ≥2.5 mm/yr): EUS + cyst fluid analysis/surveillance.

Before: Routine pancreatic resection for all branch-duct IPMNs ≥3 cm or benign serous cystadenomas.

Now: Serous cystadenoma (microcystic honeycomb/central scar, low CEA, high glucose): observe unless symptomatic. Main-duct IPMN (MPD ≥10 mm) or Branch-Duct IPMN with High-Risk Stigmata (obstructive jaundice, enhancing mural nodule ≥5 mm, MPD ≥10 mm, positive/high-grade cytology): oncologic pancreatectomy (Whipple or distal pancreatectomy) in fit patients. BD-IPMN with Worrisome Features (cyst ≥3 cm, MPD 5–9 mm, mural nodule <5 mm, growth ≥2.5 mm/yr): EUS + cyst fluid analysis/surveillance.

Pancreatic cystic neoplasms (Serous Cystadenoma, Mucinous Cystic Neoplasm, and Intraductal Papillary Mucinous Neoplasm [IPMN]).

Prevents high-morbidity pancreatectomy in indolent branch-duct IPMNs (<2–3% 5-year malignancy risk when high-risk stigmata are absent) while resecting high-grade dysplasia/early invasive cancer promptly.

• 2024 Kyoto International Consensus Guidelines on IPMN — as cited in Addendum §10.1
• European Pancreatic Cyst Guidelines — as cited in Addendum §10.1

Stratify by ASGE 2019 criteria: (1) High Risk (>50% probability: visualized CBD stone on US/CT, clinical ascending cholangitis, OR total bilirubin >4.0 mg/dL AND dilated CBD >6 mm with gallbladder in situ) → direct therapeutic ERCP or single-stage laparoscopic cholecystectomy + common bile duct exploration (LCBDE) per EAES/KSUMC 2022 rapid guideline (PMID 36229556); (2) Intermediate Risk (10%–50% probability: bilirubin 1.8–4.0 mg/dL, isolated dilated CBD >6 mm without bilirubin >4.0 mg/dL, abnormal non-bilirubin LFTs, age >55 years, or gallstone pancreatitis) → MRCP, EUS, or intraoperative cholangiography (IOC); (3) Low Risk (<10% probability: normal LFTs and normal-caliber CBD) → laparoscopic cholecystectomy without further ductal imaging.

Before: Routine diagnostic ERCP prior to cholecystectomy in intermediate-risk patients.

Now: Stratify by ASGE 2019 criteria: (1) High Risk (>50% probability: visualized CBD stone on US/CT, clinical ascending cholangitis, OR total bilirubin >4.0 mg/dL AND dilated CBD >6 mm with gallbladder in situ) → direct therapeutic ERCP or single-stage laparoscopic cholecystectomy + common bile duct exploration (LCBDE) per EAES/KSUMC 2022 rapid guideline (PMID 36229556); (2) Intermediate Risk (10%–50% probability: bilirubin 1.8–4.0 mg/dL, isolated dilated CBD >6 mm without bilirubin >4.0 mg/dL, abnormal non-bilirubin LFTs, age >55 years, or gallstone pancreatitis) → MRCP, EUS, or intraoperative cholangiography (IOC); (3) Low Risk (<10% probability: normal LFTs and normal-caliber CBD) → laparoscopic cholecystectomy without further ductal imaging.

Adults with symptomatic cholelithiasis and suspected common bile duct stones. Outcomes rated in the matrix: stone clearance and post-ERCP pancreatitis avoidance.

ERCP is primarily a therapeutic procedure carrying clinically meaningful adverse-event risks: post-ERCP pancreatitis occurs in ~3.5%–5% of unselected patients and up to 8%–15% in high-risk subsets in meta-analyses (varying with patient susceptibility, cannulation difficulty, and rectal NSAID/pancreatic stent prophylaxis). Non-invasive MRCP/EUS or IOC avoids diagnostic ERCP in the 60%–70% of intermediate-risk patients without CBD stones.

Saudi-collaborative position (§3.0 Saudi/GCC frame): the EAES / King Saud University Medical City GRADE guideline (Boni, Amer et al., PMID 36229556), co-developed with the KSUMC Clinical Practice Guidelines Unit, supports single-stage LCBDE or intraoperative ERCP when expertise and theatre logistics exist, and two-stage preoperative ERCP + laparoscopic cholecystectomy where single-stage logistics are unavailable.

• EAES / KSUMC 2022 Rapid Guideline — Boni, Amer et al. (PMID 36229556)
• ASGE 2019 / ESGE 2019 Choledocholithiasis Guidelines — as cited in Table 3.1